Home » Newsletters » BioWorld Science

BioWorld Science

May 10, 2022

View Archived Issues

Targeting NMNAT2 confers neuroprotection in glaucoma

Hangzhou Zhongmei Huadong Pharmaceutical divulges GLP-1 receptor agonists

Universite du Luxembourg discloses new PDE6D inhibitors

Ranok Therapeutics presents new CHAMPs for cancer

Beijing Jacobio Pharmaceuticals identifies new glutaminase inhibitors

Shanghai De Novo Pharmatech synthesizes new ATR kinase inhibitors

Discovery of potent and orally bioavailable CSNK1A1 inhibitors

Clec9A-M2e construct may be a step towards a universal influenza vaccine

ANGPTL7 as a novel therapeutic target for glaucoma

TBK1 inhibition is neuroprotective in optic neuropathies

iBio presents preclinical data on monoclonal antibody candidate IBIO-101 for solid tumors

Ichnos selects trispecific antibody ISB-2001 for development in multiple myeloma

Aqilion advances program for chronic inflammatory bowel disease

Researchers develop a murine model of TEK Schlemm's canal conditional knockdown glaucoma

Comparative study focuses lens of human reproductive aging

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 9, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...